- Home
- BCDA vs ABTS Comparison
BCDA vs ABTS Comparison
Compare BCDA & ABTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- ABTS
- Stock Information
- Founded
- BCDA N/A
- ABTS 2010
- Country
- BCDA United States
- ABTS Hong Kong
- Employees
- BCDA N/A
- ABTS N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- ABTS Computer Software: Programming Data Processing
- Sector
- BCDA Health Care
- ABTS Technology
- Exchange
- BCDA Nasdaq
- ABTS Nasdaq
- Market Cap
- BCDA 11.0M
- ABTS 9.8M
- IPO Year
- BCDA N/A
- ABTS N/A
- Fundamental
- Price
- BCDA $2.12
- ABTS $5.12
- Analyst Decision
- BCDA Strong Buy
- ABTS
- Analyst Count
- BCDA 1
- ABTS 0
- Target Price
- BCDA $25.00
- ABTS N/A
- AVG Volume (30 Days)
- BCDA 204.0K
- ABTS 51.9K
- Earning Date
- BCDA 08-12-2025
- ABTS 08-16-2025
- Dividend Yield
- BCDA N/A
- ABTS N/A
- EPS Growth
- BCDA N/A
- ABTS N/A
- EPS
- BCDA N/A
- ABTS N/A
- Revenue
- BCDA $3,000.00
- ABTS $6,711,225.00
- Revenue This Year
- BCDA N/A
- ABTS N/A
- Revenue Next Year
- BCDA N/A
- ABTS N/A
- P/E Ratio
- BCDA N/A
- ABTS N/A
- Revenue Growth
- BCDA N/A
- ABTS 299.11
- 52 Week Low
- BCDA $1.63
- ABTS $1.35
- 52 Week High
- BCDA $4.66
- ABTS $14.10
- Technical
- Relative Strength Index (RSI)
- BCDA 44.60
- ABTS 61.40
- Support Level
- BCDA $1.98
- ABTS $3.53
- Resistance Level
- BCDA $2.45
- ABTS $5.39
- Average True Range (ATR)
- BCDA 0.16
- ABTS 0.52
- MACD
- BCDA -0.01
- ABTS 0.07
- Stochastic Oscillator
- BCDA 18.00
- ABTS 78.11
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.